Letter to the EditorRe: McGuire JM. The Incidence of and Risk Factors for Emergence Delirium in U.S. Military Combat Veterans. Journal of Perianesthesia Nursing. 2012;27(4):236-45
References (13)
The incidence of and risk factors for emergence delirium in U.S. military combat veterans
J Perianesth Nurs
(2012)- et al.
Risk factors for emergence delirium in U.S. military members
J Perianesth Nurs
(2010) - et al.
Anaesthesia emergence delirium after mefloquine prophylaxis
Lancet
(1993) - et al.
Nonspecific effects of the gap junction blocker mefloquine on fast hippocampal network oscillations in the adult rat in vitro
Neuroscience
(2011) - et al.
Experiences of military CRNAs with service personnel who are emerging from general anesthesia
AANA J
(2012) - et al.
Psychiatric side effects of mefloquine: Applications to forensic psychiatry
J Am Acad Psychiatry Law
(2013)
Cited by (3)
Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine
2014, International Journal for Parasitology: Drugs and Drug ResistanceCitation Excerpt :Case reports also describe dysesthesias (Félix et al., 1985; Jha et al., 2006), disequilibrium (Patchen et al., 1989), nystagmus (Nevin, 2012a), and photophobia (Caillon et al., 1992). Although adverse neurological effects had previously been considered fully reversible (Arznei-Telegramm, 2013a), diminishing in intensity with the slow elimination of the drug (Nevin, 2013), in 2012, the U.S. Food and Drug Administration (FDA) announced it was reevaluating mefloquine specifically for concerns of an association with lasting vestibular disorder based on new signals detected from its FDA Adverse Event Reporting System (FAERS) (U.S. Food and Drug Administration, 2012). In 2013, European regulators updated the drug’s core safety profile to warn that symptoms of polyneuropathy developing during mefloquine use were associated with risk of an irreversible neurological condition (Bundesinstitut für Arzneimittel und Medizinprodukte, 2013), and FDA updated the U.S. product labeling with a boxed warning that other neurological effects including vertigo and loss of balance could be permanent in some cases (Arznei-Telegramm, 2013b; McGuire and Wilson, 2013).
Measurement of Mefloquine Exposure in Studies of Veterans’ Sleep Disorders
2020, Journal of Clinical Sleep MedicineClarifying the confusion of adult emergence delirium
2019, AANA Journal
Disclosure: Dr. Nevin receives consulting fees from attorneys representing clients alleging harm from their exposure to mefloquine and has been retained as an expert witness in criminal and civil cases involving civilians and military personnel exposed to the drug.